Merck & Co., Inc. Gain (Loss) Related to Litigation Settlement
Merck & Co., Inc. (MRK) reported Gain (Loss) Related to Litigation Settlement of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-27.
Discontinued › Income Statement › Other Income
us-gaap:GainLossRelatedToLitigationSettlement · last filed 2019-11-05
- Merck & Co., Inc. gain (loss) related to litigation settlement for the quarter ending 2018-12-31 was -$115.00M.
- Merck & Co., Inc. gain (loss) related to litigation settlement for the quarter ending 2018-09-30 was $0.00.
- Merck & Co., Inc. gain (loss) related to litigation settlement for the quarter ending 2018-06-30 was $0.00.
- Merck & Co., Inc. gain (loss) related to litigation settlement for the quarter ending 2018-03-31 was $115.00M.
- Merck & Co., Inc. gain (loss) related to litigation settlement for fiscal 2018 was $0.00.
- Merck & Co., Inc. gain (loss) related to litigation settlement for fiscal 2017 was $0.00.
- Merck & Co., Inc. gain (loss) related to litigation settlement for fiscal 2016 was -$625.00M.
- Merck & Co., Inc. gain (loss) related to litigation settlement for fiscal 2015 was $0.00.
| Period end | Gain (Loss) Related to Litigation Settlement 1 month | Gain (Loss) Related to Litigation Settlement 3 month | Gain (Loss) Related to Litigation Settlement 3 month as first filed | Gain (Loss) Related to Litigation Settlement 6 month | Gain (Loss) Related to Litigation Settlement 9 month | Gain (Loss) Related to Litigation Settlement 12 month | Gain (Loss) Related to Litigation Settlement 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2018-12-31 | -$115.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$115.00M derived: sum of 2 quarters · filed 2019-11-05 | -$115.00M derived: sum of 3 quarters · filed 2019-11-05 | $0.00 10-K · filed 2019-02-27 | |||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $0.00 derived: sum of 2 quarters · filed 2019-11-05 | $115.00M 10-Q · filed 2019-11-05 | ||||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $115.00M 10-Q · filed 2019-08-06 | |||||
| 2018-03-31 | $115.00M 10-Q · filed 2019-05-08 | ||||||
| 2018-01-31 | $115.00M 10-Q · filed 2018-11-06 | ||||||
| 2017-12-31 | $0.00 10-K · filed 2019-02-27 | ||||||
| 2017-02-28 | -$80.00M 10-K · filed 2018-02-27 | ||||||
| 2016-12-31 | -$742.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$740.00M derived: sum of 2 quarters · filed 2019-02-27 | -$625.00M derived: sum of 3 quarters · filed 2019-02-27 | -$625.00M 10-K · filed 2019-02-27 | |||
| 2016-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $117.00M derived: sum of 2 quarters · filed 2016-11-07 | $117.00M 10-Q · filed 2016-11-07 | ||||
| 2016-06-30 | $115.00M 10-Q · filed 2016-08-08 | $115.00M 10-Q · filed 2016-08-08 | |||||
| 2015-12-31 | $0.00 10-K · filed 2018-02-27 | -$680.00M 10-K · filed 2016-02-26 | |||||
| 2014-12-31 | $0.00 10-K · filed 2017-02-28 | ||||||
| 2013-12-31 | $0.00 10-K · filed 2016-02-26 | ||||||
| 2012-12-31 | -$493.00M 10-K · filed 2015-02-27 | ||||||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $0.00 derived: sum of 2 quarters · filed 2014-02-27 | $0.00 derived: sum of 3 quarters · filed 2014-02-27 | -$500.00M 10-K · filed 2014-02-27 | $500.00M 10-K · filed 2012-02-28 | ||
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $0.00 derived: sum of 2 quarters · filed 2012-11-09 | -$500.00M 10-Q · filed 2012-11-09 | -$500.00M derived: sum of 4 quarters · filed 2013-02-28 | |||
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | -$500.00M 10-Q · filed 2012-08-07 | -$500.00M derived: sum of 3 quarters · filed 2013-02-28 | -$1.45B derived: sum of 4 quarters · filed 2013-02-28 | |||
| 2011-04-30 | $500.00M 10-Q · filed 2011-05-09 | ||||||
| 2011-03-31 | -$500.00M 10-Q · filed 2012-05-08 | $500.00M 10-Q · filed 2011-05-09 | -$500.00M derived: sum of 2 quarters · filed 2013-02-28 | -$1.45B derived: sum of 3 quarters · filed 2013-02-28 | |||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | -$950.00M derived: sum of 2 quarters · filed 2013-02-28 | -$950.00M 10-K · filed 2013-02-28 | $950.00M 10-K · filed 2011-02-28 | |||
| 2010-09-30 | -$950.00M 10-Q · filed 2011-11-08 | -$950.00M 10-Q · filed 2011-11-08 | |||||
| 2009-12-31 | $0.00 10-K · filed 2010-03-01 | ||||||
| 2008-12-31 | $0.00 10-K · filed 2010-03-01 | ||||||
| 2007-12-31 | -$4.85B 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |